At present, programmed death‐1 (PD‐1)/programmed death ligand‐1 (PD‐L1) inhibitors play a very important role in the standard treatment of advanced NSCLC and extensive stage SCLC. This evidence concerns the gene CD274 and small cell lung carcinoma.